Lupin Limited

NSEI:LUPIN Stock Report

Market Cap: ₹1.0t

Lupin Valuation

Is LUPIN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LUPIN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
₹1.47k
Fair Value
49.4% overvalued intrinsic discount
35
Number of Analysts

Below Fair Value: LUPIN (₹2201.15) is trading above our estimate of fair value (₹1473.53)

Significantly Below Fair Value: LUPIN is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LUPIN?

Key metric: As LUPIN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for LUPIN. This is calculated by dividing LUPIN's market cap by their current earnings.
What is LUPIN's PE Ratio?
PE Ratio38.2x
Earnings₹26.26b
Market Cap₹1.00t

Price to Earnings Ratio vs Peers

How does LUPIN's PE Ratio compare to its peers?

The above table shows the PE ratio for LUPIN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average37.9x
ZYDUSLIFE Zydus Lifesciences
22.1x-1.8%₹1.0t
500124 Dr. Reddy's Laboratories
19.3x-1.2%₹1.0t
MANKIND Mankind Pharma
50.9x17.4%₹1.0t
500420 Torrent Pharmaceuticals
59.2x23.3%₹1.1t
LUPIN Lupin
38.2x16.5%₹1.0t

Price-To-Earnings vs Peers: LUPIN is expensive based on its Price-To-Earnings Ratio (38.2x) compared to the peer average (37.9x).

Price to Earnings Ratio vs Industry

How does LUPIN's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$69.62m
524652 Ind-Swift
1.5xn/aUS$9.61m
No more companies available in this PE range
LUPIN 38.2xIndustry Avg. 31.9xNo. of Companies18PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: LUPIN is expensive based on its Price-To-Earnings Ratio (38.2x) compared to the Indian Pharmaceuticals industry average (31.9x).

Price to Earnings Ratio vs Fair Ratio

What is LUPIN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LUPIN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio38.2x
Fair PE Ratio40.5x

Price-To-Earnings vs Fair Ratio: LUPIN is good value based on its Price-To-Earnings Ratio (38.2x) compared to the estimated Fair Price-To-Earnings Ratio (40.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst LUPIN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹2,201.15
₹2,276.46
+3.4%
11.8%₹2,800.00₹1,671.00n/a35
Jan ’26₹2,364.90
₹2,205.50
-6.7%
14.3%₹2,750.00₹1,300.00n/a36
Dec ’25₹2,050.75
₹2,193.54
+7.0%
14.5%₹2,750.00₹1,300.00n/a37
Nov ’25₹2,197.70
₹2,027.00
-7.8%
17.5%₹2,750.00₹1,300.00n/a37
Oct ’25₹2,194.40
₹1,974.92
-10.0%
18.0%₹2,515.00₹1,284.00n/a36
Sep ’25₹2,240.20
₹1,941.91
-13.3%
17.3%₹2,443.00₹1,284.00n/a35
Aug ’25₹1,953.35
₹1,632.49
-16.4%
12.5%₹1,958.00₹1,221.00n/a35
Jul ’25₹1,616.05
₹1,583.75
-2.0%
13.1%₹1,958.00₹1,192.00n/a36
Jun ’25₹1,582.55
₹1,577.42
-0.3%
12.6%₹1,952.00₹1,192.00n/a36
May ’25₹1,645.90
₹1,508.69
-8.3%
15.7%₹1,949.00₹840.00n/a36
Apr ’25₹1,623.75
₹1,509.40
-7.0%
13.6%₹1,949.00₹1,123.00n/a35
Mar ’25₹1,624.55
₹1,503.06
-7.5%
14.2%₹1,949.00₹1,080.00n/a36
Feb ’25₹1,513.70
₹1,208.11
-20.2%
15.6%₹1,593.00₹900.00₹2,056.2535
Jan ’25₹1,312.85
₹1,150.41
-12.4%
17.0%₹1,593.00₹816.00₹2,364.9037
Dec ’24₹1,296.65
₹1,116.61
-13.9%
15.9%₹1,451.00₹740.00₹2,050.7538
Nov ’24₹1,132.75
₹994.37
-12.2%
17.7%₹1,300.00₹660.00₹2,197.7038
Oct ’24₹1,171.25
₹953.05
-18.6%
16.9%₹1,300.00₹660.00₹2,194.4038
Sep ’24₹1,093.85
₹948.87
-13.3%
17.0%₹1,300.00₹660.00₹2,240.2039
Aug ’24₹988.20
₹778.67
-21.2%
15.0%₹1,300.00₹643.00₹1,953.3539
Jul ’24₹902.75
₹775.11
-14.1%
15.3%₹1,300.00₹643.00₹1,616.0538
Jun ’24₹812.15
₹749.34
-7.7%
16.2%₹1,300.00₹572.00₹1,582.5538
May ’24₹709.50
₹713.55
+0.6%
17.8%₹1,300.00₹555.00₹1,645.9038
Apr ’24₹648.40
₹718.97
+10.9%
17.6%₹1,300.00₹555.00₹1,623.7538
Mar ’24₹661.40
₹731.53
+10.6%
18.6%₹1,300.00₹555.00₹1,624.5540
Feb ’24₹737.40
₹759.77
+3.0%
17.0%₹1,300.00₹580.00₹1,513.7039
Analyst Price Target
Consensus Narrative from 35 Analysts
₹2.28k
Fair Value
3.4% undervalued intrinsic discount
35
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 18:26
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lupin Limited is covered by 75 analysts. 35 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nitin BhasinAmbit Capital
Prashant NairAmbit Capital
null nullAnand Rathi Shares and Stock Brokers Limited